BACKGROUND
All targeted therapies approved for ROS1-fusion-positive non-small cell lung cancer (NSCLC) are type I inhibitors. These TKIs may induce resistance amenable to type II inhibition. Cabozantinib is a type II ROS1/MET tyrosine kinase inhibitor with preclinical activity against on-target ROS1 resistance mutation...
J. Rubio-Perez, M. Repetto, Ling-Feng Ye et al.· Clinical Cancer Research· 0 citations
582
Background:
Timely, comprehensive biomarker testing is essential to identify actionable genomic alterations and guide targeted therapy in patients with advanced solid tumors. However, community and academic cancer centers often encounter delays in ordering, prolonged turnaround from diagnosis to results, an...
Amany R. Keruakous, W. Waugh, Samuel K. Caughron et al.· JCO Oncology Practice· 0 citations
T-DM1 demonstrated heterogenous efficacy among HER2-amplified tumor types, with promising response and outcomes among patients with salivary gland cancer.
J. Ross, W. Wong, Lauren Schoech et al.· Clinical Cancer Research· 0 citations
SMARCA4 alteration class and allelic status define biologically and clinically distinct subsets of tumors and support incorporating allelic status and functional mutation class into patient selection strategies for emerging BRM-targeted therapies.
M. Repetto, M. Gormally, Jason Chang et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.